| Initial Public Offering of 11,676,470 equity shares of face value of Rs. 2 each ("equity shares") of Rossari Biotech Limited (the "company" or the "issuer") for cash at a price of Rs. 425 per equity share (including a share premium of Rs. 423 per equity share) (the "offer price") aggregating to Rs. 496.25 Crores comprising a fresh issue of 1,176,470 equity shares aggregating to Rs. 50* Crores (the "fresh issue") and an offer for sale of 10,500,000 equity shares (the "offered shares") aggregating to Rs. 44.63 Crores, comprising an offer for sale of 5,250,000 equity shares aggregating to Rs. 22.31 Crores by Mr. Edward Menezes and 5,250,000 equity shares aggregating to Rs. 22.31 Crores by Mr. Sunil Chari (the "promoter selling shareholders" or the "selling shareholders"), (the "offer for sale", and together with the fresh issue, the "offer"). The offer shall constitute 22.49% of the post-offer paid up equity share capital of the company.
The company has, in consultation with the book running lead managers ("brlms"), undertaken a private placement of equity shares aggregating to Rs. 99.999 Crores ("pre-ipo placement"). The size of the fresh issue of up to Rs. 150 Crores has been reduced by Rs. 99.999 Crores pursuant to the pre-ipo placement and accordingly, the size of the fresh issue is up to Rs. 50. Crores
|